NCT07065669 Treating Adolescent Obsessive Compulsive Disorder With Transcranial Magnetic Stimulation
| NCT ID | NCT07065669 |
| Status | Recruiting |
| Phase | — |
| Sponsor | University of California, San Francisco |
| Condition | Obsessive-Compulsive Disorder |
| Study Type | INTERVENTIONAL |
| Enrollment | 30 participants |
| Start Date | 2025-06-01 |
| Primary Completion | 2027-07-01 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 30 participants in total. It began in 2025-06-01 with a primary completion date of 2027-07-01.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
This is a pilot study to examine the tolerability, safety and early efficacy of two forms of transcranial magnetic stimulation (TMS) for treating adolescents with Obsessive Compulsive Disorder (OCD) who have experienced limited improvements with usual treatments for OCD in adolescents. The project's primary goal is to examine whether adolescents can complete 3 consecutive weeks of TMS administered 5 days per week, and to describe the type of and how common individual side effects with TMS occur in adolescents with OCD. Participants will: * visit the clinic every weekday for 3 weeks (15 days) to receive TMS treatments * have a brain MRI scan before TMS treatments begins and after finishing all TMS * complete questionnaires and report changes in behavior and physical symptoms
Eligibility Criteria
Inclusion Criteria: 1. outpatients 2. ages 13 - 17 years 3. meets current DSM-5 criteria for Obsessive Compulsive Disorder with screening CY-BOCS II score \> 16 (moderate to severe). 4. stable on chronic psychotropic medications and/or therapy for 8 weeks prior to the study and agreeable to continue throughout the study without changes. 5. participants may continue to take medications and record daily usage throughout the study. 6. capacity to provide informed assent and parent or legal guardian able to provide consent. 7. ability to tolerate clinical study procedures. 8. successfully complete the screening forms without any contraindications. Exclusion Criteria: 1. Psychiatric: history of schizophrenia, bipolar disorder, substance/alcohol abuse disorder, current elevated suicide risk, prior psychosurgery, prior ECT. 2. Neurologic: severe neurocognitive disorder, seizure disorder, certain structural brain lesions (e.g., intracranial mass lesions, hydrocephalus, sequelae of meningitis, frank brain injury). 3. TMS contraindications: implanted device; presence of metal in the head, including eyes and ears (excluding dental implants); certain tics; medications or systemic illness that predispose seizure risk; family history of 1st degree relative with seizure disorder. 4. Subjects with an unstable physical, systemic, or metabolic disorder (e.g., unstable hypertension, malnutrition secondary to eating disorder). 5. Females who are pregnant or nursing (as determined by a questionnaire and pregnancy test). 6. Current and anticipated continued treatment with excluded medication (See prohibited list). 7. Inability to complete the research protocol as determined by the Principal Investigator.
Contact & Investigator
James T McCracken, MD
PRINCIPAL INVESTIGATOR
University of California, San Francisco
Frequently Asked Questions
Who can join the NCT07065669 clinical trial?
This trial is open to participants of all sexes, aged 13 Years or older, up to 17 Years, studying Obsessive-Compulsive Disorder. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07065669 currently recruiting?
Yes, NCT07065669 is actively recruiting participants. Contact the research team at ocdteenTMS@ucsf.edu for enrollment information.
Where is the NCT07065669 trial being conducted?
This trial is being conducted at San Francisco, United States.
Who is sponsoring the NCT07065669 clinical trial?
NCT07065669 is sponsored by University of California, San Francisco. The principal investigator is James T McCracken, MD at University of California, San Francisco. The trial plans to enroll 30 participants.